Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer.

Kawashima M, Iwamoto N, Kawaguchi-Sakita N, Sugimoto M, Ueno T, Mikami Y, Terasawa K, Sato TA, Tanaka K, Shimizu K, Toi M.

Cancer Sci. 2013 Oct;104(10):1372-9. doi: 10.1111/cas.12229. Epub 2013 Aug 6.

2.

The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer.

Goto T, Terada N, Inoue T, Nakayama K, Okada Y, Yoshikawa T, Miyazaki Y, Uegaki M, Sumiyoshi S, Kobayashi T, Kamba T, Yoshimura K, Ogawa O.

PLoS One. 2014 Feb 28;9(2):e90242. doi: 10.1371/journal.pone.0090242. eCollection 2014.

3.
4.

Matrix-assisted laser desorption/ionization mass spectrometry imaging of cell cultures for the lipidomic analysis of potential lipid markers in human breast cancer invasion.

Wang S, Chen X, Luan H, Gao D, Lin S, Cai Z, Liu J, Liu H, Jiang Y.

Rapid Commun Mass Spectrom. 2016 Feb 28;30(4):533-42. doi: 10.1002/rcm.7466.

PMID:
26777684
5.

Exploring three-dimensional matrix-assisted laser desorption/ionization imaging mass spectrometry data: three-dimensional spatial segmentation of mouse kidney.

Trede D, Schiffler S, Becker M, Wirtz S, Steinhorst K, Strehlow J, Aichler M, Kobarg JH, Oetjen J, Dyatlov A, Heldmann S, Walch A, Thiele H, Maass P, Alexandrov T.

Anal Chem. 2012 Jul 17;84(14):6079-87. doi: 10.1021/ac300673y. Epub 2012 Jul 5.

PMID:
22720760
7.

Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry.

Rauser S, Marquardt C, Balluff B, Deininger SO, Albers C, Belau E, Hartmer R, Suckau D, Specht K, Ebert MP, Schmitt M, Aubele M, Höfler H, Walch A.

J Proteome Res. 2010 Apr 5;9(4):1854-63. doi: 10.1021/pr901008d.

PMID:
20170166
8.

Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.

Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF.

Clin Cancer Res. 1999 May;5(5):1041-56.

9.

Matrix-assisted laser desorption/ionization and nanoparticle-based imaging mass spectrometry for small metabolites: a practical protocol.

Sugiura Y, Setou M.

Methods Mol Biol. 2010;656:173-95. doi: 10.1007/978-1-60761-746-4_10.

PMID:
20680591
10.

Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas.

Traub F, Jost M, Hess R, Schorn K, Menzel C, Budde P, Schulz-Knappe P, Lamping N, Pich A, Kreipe H, Tammen H.

Lab Invest. 2006 Mar;86(3):246-53.

11.

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.

Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A.

Mod Pathol. 2006 Feb;19(2):307-19.

12.
13.

Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma.

Adamkov M, Kajo K, Vybohova D, Krajcovic J, Stuller F, Rajcani J.

Neoplasma. 2012;59(1):30-7.

PMID:
22103896
14.

Mass microscopy: high-resolution imaging mass spectrometry.

Setou M, Kurabe N.

J Electron Microsc (Tokyo). 2011;60(1):47-56. doi: 10.1093/jmicro/dfq079. Epub 2010 Nov 24. Review.

PMID:
21109523
15.

ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer.

Pan J, Sun LC, Tao YF, Zhou Z, Du XL, Peng L, Feng X, Wang J, Li YP, Liu L, Wu SY, Zhang YL, Hu SY, Zhao WL, Zhu XM, Lou GL, Ni J.

J Transl Med. 2011 Dec 8;9:211. doi: 10.1186/1479-5876-9-211.

16.

Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium.

Hudelist G, Singer CF, Pischinger KI, Kaserer K, Manavi M, Kubista E, Czerwenka KF.

Proteomics. 2006 Mar;6(6):1989-2002.

PMID:
16470630
17.

Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue.

Su P, Zhang Q, Yang Q.

Diagn Pathol. 2010 Jun 18;5:38. doi: 10.1186/1746-1596-5-38.

18.

TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.

Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS, Sanlioglu S.

Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):716-23. Epub 2007 May 18.

PMID:
17512128
19.

[Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].

Ruibal A, Schneider J, Arias J, del Río MC, Núnez MJ, Tejerina A.

Rev Esp Med Nucl. 2000 Jun;19(3):244-6. Spanish. No abstract available.

20.

HER2 as a prognostic factor in breast cancer.

Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A.

Oncology. 2001;61 Suppl 2:67-72. Review.

PMID:
11694790

Supplemental Content

Support Center